Sarcopenia Measured by Ultrasound in Hospitalized Older Adults (ECOSARC)

"SARCOPENIA MEASURED BY ULTRASOUND IN HOSPITALIZED OLDER ADULTS" (ECOSARC Study).

Observational prospective study in older adults admitted to an Acute Geriatric Unit, in which sarcopenia will be evaluated by ultrasound in the anterior rectus femoris muscle.

Study Overview

• Status: Completed
• Conditions: Sarcopenia
• Intervention / Treatment: Diagnostic test: muscle ultrasound

Detailed Description

The main objective of the study is to estimate, by means of portable ultrasound, parameters of muscle quantity and quality (anterior rectus femoris muscle area, width and echostructure ) in older adults hospitalized in Acute Geriatric Units for medical reasons.

• Study Type: Observational
• Enrollment (Actual): 161

Contacts and Locations

• Study Contact: Name: Pedro Abizanda, MD, PhD; Phone Number: +34967597651; Email: pabizanda@sescam.jccm.es

Study Locations

• Spain
  • Albacete, Spain, 02006
    • Complejo Hospitalario Universitario de Albacete

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 69 years and older (Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients over 69 years of age admitted to Acute Geriatric Units.

Description

Inclusion Criteria:

• Patients over 69 years of age.
• Hospitalization for a medical cause in Acute Geriatric Units.
• Holden's Functional Ambulation Classification Scale at level 1 or higher.
• Informed consent signed by the patient or legal representative.

Exclusion Criteria:

• Terminal condition or life expectancy of less than 6 months.
• Impossibility or refusal to undergo muscle ultrasound.
• Refusal for follow-up
• Severe dementia stage Global Deteriorating Scale: 7
• Impossibility in the opinion of the investigators to complete the necessary data for the study.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of sarcopenia on admission	Prevalence of sarcopenia on admission. A prevalent case of sarcopenia will be considered if a patient fulfills the EWGSOP2 at admission	72 hours
Incidence of sarcopenia between admission and discharge	An incident case of sarcopenia will be considered if a patient not fulfilling EWGSOP2 diagnostic criteria on admission, will meet diagnostic criteria at discharge of sarcopenia at discharge (diagnosis will be considered as a dichotomous variable -yes/no-).	15 days
Muscle mass (the anterior rectus femoris muscle)	The evolution of muscle mass between admission and discharge will be assessed by ultrasound	15 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Minimal nutritional assessment (MNA-SF) score	The mini-nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in older adults. It takes into account the patient's loss of appetite, weight loss, motor skills, recent health status, neuropsychological disorders. The maximum score of the MNA-SF is 14: Greater than or equal to 11: normal nutritional status. Between 8 and 11: risk of malnutrition. Less than 8: malnutrition.	72 hours
Hand grip strength	Using a hand-held dynamometer	15 days
4-meter walking speed test	The evolution of the value of the 4-meter walking speed test between admission and discharge will be assessed.	15 days
ADL (Activities of Daily Living) questionnaire	the ADL questionnaire will also be performed on admission, at discharge, and at 3 months.	3 months
SPPB score (SHORT PHYSICAL PERFORMANCE BATTERY score)	Short Physical Performance Battery (SPPB): score range 0-12, higher score means a better outcome	15 days
Mortality	Mortality will be measured with vital status at 3 months.	3 months
Length of stay, days	Day of admission to day of discharge	15 days
Readmission(s) after index hospitalization	Readmission(s) after index hospitalization, Dichotomous outcome (yes/no)	3 months
Emergency department (ED) visit(s)	ED visit(s) after index hospitalization, Dichotomous outcome (yes/no)	3 months

Collaborators and Investigators

• Sponsor: Pedro Abizanda
• Collaborators: Puerta de Hierro University Hospital; Hospital Universitario Infanta Leonor; Hospital Universitario La Paz; Hospital Universitario Getafe; Hospital Infanta Sofia; Hospital Virgen del Valle de Toledo
• Investigators: Principal Investigator: Pedro Abizanda, MD, PhD, Complejo Hospitalario Universitario de Albacete (SESCAM)

Study record dates

Study Major Dates

• Study Start (Actual): May 28, 2019
• Primary Completion (Actual): June 30, 2022
• Study Completion (Actual): June 30, 2022

Study Registration Dates

• First Submitted: October 29, 2021
• First Submitted That Met QC Criteria: October 29, 2021
• First Posted (Actual): November 9, 2021

Study Record Updates

• Last Update Posted (Actual): August 30, 2023
• Last Update Submitted That Met QC Criteria: August 29, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: ultrasound; sarcopenia; hospitalized; aged
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Sarcopenia
• Other Study ID Numbers: ABZ-ECO-2018-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No